Document is current
Any future updates will be listed below
-
Authors
Sánchez-de-Diego, Cristina
Yada, Ravi Chandra
Sethakorn, Nan https://orcid.org/0000-0002-7395-3182
Geiger, Peter G.
Ding, Adeline B.
Heninger, Erika https://orcid.org/0000-0003-0166-9972
Ahmed, Fauzan
Virumbrales-Muñoz, María https://orcid.org/0000-0003-3660-8651
Lupsa, Nikolett
Bartels, Emmett
Stewart, Kacey
Ponik, Suzanne M. https://orcid.org/0000-0003-1367-4349
Sharifi, Marina N. https://orcid.org/0000-0003-0128-3033
Lang, Joshua M. https://orcid.org/0000-0002-0943-8872
Beebe, David J. https://orcid.org/0000-0002-0415-9006
Kerr, Sheena C. https://orcid.org/0000-0002-4404-3382
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (Prostate SPORE P50CA269011)
- License Information
-
More Information
Article History
Received: 4 December 2024
Accepted: 13 June 2025
First Online: 1 July 2025
Competing interests
: The authors declare the following competing interests: D.J.B. holds equity in Bellbrook Labs LLC, Tasso Inc., Salus Discovery LLC, Lynx Biosciences Inc., Stacks to the Future LLC, Flambeau Diagnostics LLC and Onexio Biosystems LLC. D.J.B. is also a consultant for Abbott Laboratories. J.M.L. served as paid consultant/received honoraria from Sanofi, AstraZeneca, Gilead, Pfizer, Astellas, Seattle Genetics, Janssen and Immunomedics. N.S. served as paid advisory board consultant to Amgen. M.N.S. reports institutional research support from Novartis unrelated to the current study.
: Inclusion and Ethics: All patients provided written, informed consent under an Institutional Review Board (IRB) approved protocol at the University of Wisconsin-Madison. All ethical regulations relevant to human research participants were followed.
